As biological and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have proliferated, the cost of care has begun to inflate with a questionable associated benefit to patients. This “bubble” is unsustainable, according to one expert, and rheumatologists should work to help deflate it. “By putting a high price on newly approved biological and targeted synthetic DMARDs, ...
Opinion: Can rheumatologists help deflate an unsustainable DMARD pricing bubble?
By Dave Levitan
3 Mar 2021